Allergan, Inc. (NYSE:AGN)
A technology-driven, global health care company which discovers, develops and commercializes pharmaceutical and medical device products for markets such as ophthalmic, neurological, medical aesthetics, medical dermatological etc.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
JorgeAura
(< 20)
Submitted: 2/2/2013 7:16:27 PM :
Start Price:
$106.15
AGN Score:
+14.64
sp500 in maximums.
Recs
JasonLaub
(< 20)
Submitted: 1/29/2013 1:14:36 AM :
Start Price:
$106.29
AGN Score:
-15.17
Strong growth in multiple markets, especially in Botox - it was recently approved to treat overactive bladder.
Recs
ikkyu2
(99.46)
Submitted: 3/12/2012 7:12:19 PM :
Start Price:
$91.60
AGN Score:
-9.02
BoTox is a verb and is the only FDA-approved treatment for chronic migraine, which is maybe the #2 or #3 contributor of lost work days in the country. And it actually works. I don't think Allergan can help but grow earnings from here.
Recs
NevDullNJ
(< 20)
Submitted: 2/8/2012 1:22:22 PM :
Start Price:
$88.83
AGN Score:
-8.67
Many of Allergan's products are tied to the notion of "you, just better". As we're entering this "halftime in America" period, if we'll be doing better we'll want to feel better about ourselves, and AGN will be there to take our money.
Recs
Fitpitcher
(65.70)
Submitted: 2/3/2012 11:31:18 AM :
Start Price:
$81.31
AGN Score:
+4.97
Great management. Aesthetic product line will pick up with rebounding economy
Recs
missyjcase
(40.13)
Submitted: 6/27/2011 10:31:39 AM :
Start Price:
$80.59
AGN Score:
-3.93
lots of medications & patents
Recs
daviddeweaver
(< 20)
Submitted: 2/20/2011 12:24:18 PM :
Start Price:
$73.82
AGN Score:
+12.98
The trend for the past year on AGN seems to show that over the long run the stock has a lot of faith from investors, and over time it produces consistent gains. However, the faith in the company will seem rather unjustified in a couple of years, which will not necessarily mean a downturn in price, but it will no longer outperform the market.
Recs
oldmanarchitect
(32.43)
Submitted: 12/10/2010 7:08:21 AM :
Start Price:
$68.61
AGN Score:
+14.41
The Lap Band will soon be approved for obesity, rather than limited to morbidly obese. Procedure has only been used on 300,000 patients so far and makes up a rather small portion of the AGN profits. Foresee Lap Band profits doubling within the next 5 years.
Botox will continue its domination of market share, and with new procedural uses coming on line (Migraine, seizure) - Botox will double use within next three years
Recs
stuinkc
(85.16)
Submitted: 11/4/2010 4:56:56 PM :
Start Price:
$72.87
AGN Score:
+3.80
You're so vain, you probably think this song is about you....
Recs
dkraljic
(< 20)
Submitted: 8/8/2010 9:09:39 AM :
Start Price:
$64.38
AGN Score:
+10.87
Botox is already hot. Latisse is moving ahead strongly. And Botox indication for Migraine is pending approval.
Recs
foolontherocks
(82.53)
Submitted: 12/18/2009 1:24:27 AM :
Start Price:
$59.87
AGN Score:
+19.11
botox will stay popular
Recs
COOLSTOCK
(70.59)
Submitted: 6/12/2009 11:00:44 AM :
Start Price:
$45.20
AGN Score:
+47.37
good company
Recs
akdag
(< 20)
Submitted: 2/26/2009 10:31:48 AM :
Start Price:
$40.51
AGN Score:
+48.41
Very successful product line with not much comparable competition (Botox, Juvederm). They also developed less expensive and evasive procedures like eye lash treatments. Especially during tough eco times personal (and more affordable) luxuries like the lash and various derma treatments will allow revenue targets being met. AGN will be doing fine b/c of the current economy.
Recs
sashamore
(60.19)
Submitted: 12/31/2008 12:24:19 PM :
Start Price:
$39.49
AGN Score:
+69.56
great new cosmetic product approved by fda will increase sales
Recs
dissinj
(41.49)
Submitted: 12/4/2008 4:04:56 PM :
Start Price:
$35.54
AGN Score:
+82.16
The potential that Lumigan will explode profits with little in the way of adverse events. A real positive for a Pharma company.
Recs
mukwonago53149
(< 20)
Submitted: 12/3/2008 8:30:27 PM :
Start Price:
$36.42
AGN Score:
+80.93
http://www.thestreet.com/story/10451209/1/cramers-mad-money-recap-let-the-deals-begin.html?puc=_htmlbooyah
Recs
MViscio1
(99.75)
Submitted: 10/23/2008 11:57:41 AM :
Start Price:
$35.22
AGN Score:
+100.82
HEALTH CARE COMPANY
Recs
JoyofMoney
(71.60)
Submitted: 7/9/2008 2:32:51 AM :
Start Price:
$51.58
AGN Score:
+64.12
Terrible P/E ratios but the rest of the fundamentals were good enough to sell me. Medical devices, a complement to pharmaceutical as well as a specialty pharmaceutical niche. Had narrow movement in stock price in the past few weeks and I liked the price being toward its 52 week low. Optimistically, I am looking for strength out of this one in a market that is volatile.
Recs
biovestor
(< 20)
Submitted: 6/28/2008 10:29:35 AM :
Start Price:
$50.98
AGN Score:
+65.39
A leader in cosmetic medicine in a US market obsessed with appearance and a growing Baby Boomer population.
Recs
eslavs
(< 20)
Submitted: 6/23/2008 9:17:45 PM :
Start Price:
$52.07
AGN Score:
-64.55
I work in ophthalmology, and I see a segment of this company's products. In our industry, most are top-notch. However, looking ahead to uncertain economic times, increased competition and possible regulation, I don't think Botox is going to be as hot a product as it has been. My bet is Allergan will continue to slide.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 54 : 1 2 3 Next »